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Abstract: [18F]FluorTriopride ([18F]FTP) is a dopamine D3-receptor preferring radioligand with potential for investigation of neuropsychiatric disorders including Parkinson disease, dystonia and schizophrenia. Here we estimate human radiation dosimetry for [18F]FTP based on the ex-vivo biodistribution in rodents and in vivo distribution in nonhuman primates. Biodistribution data were generated using male and female Sprague-Dawley rats injected with ~370
KBq of [18F]FTP and euthanized at 5, 30, 60, 120, and 240 min. Organs of interest were dissected, weighed and
assayed for radioactivity content. PET imaging studies were performed in two male and one female macaque fascicularis administered 143-190 MBq of [18F]FTP and scanned whole-body in sequential sections. Organ residence
times were calculated based on organ time activity curves (TAC) created from regions of Interest. OLINDA/EXM 1.1
was used to estimate human radiation dosimetry based on scaled organ residence times. In the rodent, the highest absorbed radiation dose was the upper large intestines (0.32-0.49 mGy/MBq), with an effective dose of 0.07
mSv/MBq in males and 0.1 mSv/MBq in females. For the nonhuman primate, however, the gallbladder wall was the
critical organ (1.81 mGy/MBq), and the effective dose was 0.02 mSv/MBq. The species discrepancy in dosimetry
estimates for [18F]FTP based on rat and primate data can be attributed to the slower transit of tracer through the
hepatobiliary track of the primate compared to the rat, which lacks a gallbladder. Out findings demonstrate that
the nonhuman primate model is more appropriate model for estimating human absorbed radiation dosimetry when
hepatobiliary excretion plays a major role in radiotracer elimination.
Keywords: [18F]FluorTriopride, PET, dosimetry, Fluorine-18, D3 receptors, Parkinson disease

Introduction
[18F]FluorTriopride ([18F]FTP) is a unique dopamine D3-receptor (D3R) preferring radioligand
with potential for investigation of neuropsychiatric disorders including Parkinson disease,
dystonia and schizophrenia. D3R belongs to
the family of D2-like receptors (D2R, D3R,
D4R), which are coupled to Gi and inhibit adenyl
cyclase [1, 2]. D3R like D2R are expressed in
striatum, but the data suggest that D3R is
expressed predominantly in ventral (limbic) and
to a lesser (although still substantial) degree in
dorsal (motor) striatum [3]. Various studies suggest that D2R and D3R may be regulated differently in Parkinson disease [4-6], schizophrenia

[7, 8], and substance abuse [9, 10]. Recent
data also hint toward abnormalities in striatal
D3R in dystonia [11]. One of the major obstacles to better understanding of the D2R/D3R
dynamic in such conditions has been lack of
selective ligands for in vivo molecular imaging
studies. Among numerous D2-like receptor
ligands, only [18F](N-methyl)benperidol (NMB)
provides specificity for D2R, with a 200-fold
selectivity for D2R versus D3R [11]. We have
recently validated a new radioligand [18F]FTP
which has a 160-fold selectivity for D3R versus
D2R [12]. The objective of this study is to determine the organ distribution of [18F]FTP in rodent
and nonhuman primate species of animals to
estimate human absorbed radiation dosimetry.

Dosimetry study of a D3 receptor PET radioligand [18F]FTP
approved by the Animal Studies Committee of
Washington University in Saint Louis.
Rodent biodistribution

Figure 1. Schematic of data acquisition in primates
using small animal PET imaging. Seven to eight successive PET scans of increasing duration were obtained in four positions: A (whole brain), B (heart and
lungs), C (liver, gallbladder and kidneys), and D (urinary bladder, small and large intestines).

Specifically, we used ex-vivo biodistribution experiments in Sprague-Dawley rats and noninvasive PET imaging studies of tissue kinetics in
macaque fascicularis. These dosimetry estimates will facilitate application of [18F]FTP for
PET imaging studies of D3 receptors in human
subjects.
Materials and methods
Radiopharmaceutical preparation
[18F]FTP was prepared using an automated system based on published synthetic methods
[12-14]. [18F]Fluoride was produced by the
18
O(p, n)18F nuclear reaction induced on an isotopically-enriched [18O]water target using the
Washington University RDS Eclipse cyclotron. A
nucleophilic displacement reaction was used to
synthesize [18F]FTP starting with the corresponding mesylate and [18F]fluoride. The radiolabeled product was isolated using semi-preparative HPLC. [18F]FTP was reformulated in
ethanolic saline for Injection, USP (1/10 v/v)
and sterilized by terminal filtration. The radiochemical purity of the radiopharmaceutical
product was over 95%, and the end-of-synthesis specific activity exceeded 74 TBq/mmol.
Animal protections
All applicable international, national, and institutional guidelines for the care and use of
rodents and nonhuman primates were followed. Procedures used in this work were
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Twenty male (200-245 gram) and 20 female
(170-210 gram) Sprague Dawley rats were
administered ~370 KBq of [18F]FTP in 100 µL
via intravenous tail vein injection. The animals
were maintained in metabolic cages for collection of urine and feces excretion. Animals were
euthanized in groups of four at: 5 min, 30 min,
60 min, 120 min, and 240 min post injection of
[18F]FTP. The organs were harvested, and the
percent injected dose per gram (%ID/gram) was
determined by measuring the radioactivity in
weighed samples, and comparison to that of a
standard sample of the injectate.
The organ residence times were calculated by
numerical integration (trapezoid method) of the
time activity data expressed in %ID/gram of tissue. The following initial organ activity immediately after injection was assumed based on the
respective blood volumes: lungs, 5.9%; liver,
2.9%; spleen and kidneys, each 1.5%; bone,
3.7%. The remainder of activity (72%) was
assigned to the blood compartment. Blood and
bone mass were assumed to be 8% and 15% of
the total body mass, respectively.
The cumulative activities (%ID) in the urine and
feces activities were plotted as a function of
time, and an uptake function [F(t) = A0 (1-exp(A1 t))] was fitted to the data. We then calculated
a bladder residence time using the values of A0
and A1 in the MIRD bladder voiding model,
assuming a voiding interval of 1 hr. The animal
organ residence times were scaled to human
organ weights according to the “relative organ
mass scaling” method [15].
The above technique was employed for all
organs except the small and large intestines,
due to the high accumulation of radioactivity in
these organs. We instead applied the percent
injected dose in the entire organs as measured
in the animal biodistribution experiments. The
remainder of the body residence time was calculated as 70% of the injected activity deposited in blood, fat and all other unaccounted tissues. The remainder was defined as the maximum residence time of F-18 activity minus the
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Table 1. Biodistribution of [18F]FTP in male Sprague-Dawley rats expressed as percent injected dose
per gram of tissue (%ID/g). Each set of data is the mean ± SD for n = 4 animals at each time point
Blood
Lung
Liver
Spleen
Kidney
Muscle
Fat
Heart
Brain
Bone
Marrow
Testes/Uterus
Prostate/Ovaries
Adrenals
Thyroid
Pancreas
Thymus
Stomach
Small intestine
Upper large intestine
Lower large intestine

5 min
0.176 ± 0.041
5.948 ± 0.354
2.999 ± 0.414
2.693 ± 0.830
3.725 ± 0.321
0.176 ± 0.027
0.130 ± 0.018
1.169 ± 0.185
0.257 ± 0.023
0.564 ± 0.053
0.836 ± 0.214
0.152 ± 0.014
0.587 ± 0.247
3.767 ± 1.049
0.863 ± 0.158
1.893 ± 0.208
0.838 ± 0.081
0.372 ± 0.129
3.239 ± 0.500
0.703 ± 0.067
0.234 ± 0.007

30 min
0.176 ± 0.012
1.601 ± 0.057
2.257 ± 0.362
1.350 ± 0.248
2.513 ± 0.203
0.182 ± 0.022
0.189 ± 0.039
0.353 ± 0.025
0.171 ± 0.010
0.413 ± 0.020
0.689 ± 0.042
0.223 ± 0.010
0.734 ± 0.086
5.838 ± 0.698
0.305 ± 0.209
1.094 ± 0.062
0.695 ± 0.052
0.410 ± 0.085
4.986 ± 0.959
2.718 ± 0.972
0.202 ± 0.013

1 hour
0.146 ± 0.015
0.497 ± 0.075
1.359 ± 0.094
0.480 ± 0.102
1.733 ± 0.225
0.094 ± 0.011
0.105 ± 0.021
0.195 ± 0.023
0.134 ± 0.010
0.249 ± 0.017
0.412 ± 0.038
0.202 ± 0.011
0.736 ± 0.310
3.868 ± 1.002
0.238 ± 0.004
0.398 ± 0.067
0.511 ± 0.057
0.344 ± 0.079
3.283 ± 1.191
9.278 ± 1.151
0.255 ± 0.048

2 hours
0.068 ± 0.056
0.205 ± 0.178
0.611 ± 0.515
0.169 ± 0.147
0.679 ± 0.550
0.046 ± 0.038
0.043 ± 0.039
0.084 ± 0.071
0.064 ± 0.054
0.158 ± 0.132
0.143 ± 0.127
0.119 ± 0.101
0.340 ± 0.326
1.806 ± 1.551
0.097 ± 0.078
0.121 ± 0.106
0.225 ± 0.185
0.170 ± 0.163
0.848 ± 0.730
7.996 ± 6.584
0.356 ± 0.356

4 hours
0.070 ± 0.013
0.183 ± 0.023
0.707 ± 0.084
0.165 ± 0.014
0.770 ± 0.024
0.048 ± 0.007
0.026 ± 0.003
0.078 ± 0.010
0.083 ± 0.011
0.292 ± 0.025
0.084 ± 0.034
0.119 ± 0.017
0.088 ± 0.084
0.798 ± 0.345
0.127 ± 0.031
0.095 ± 0.016
0.158 ± 0.030
0.057 ± 0.017
0.392 ± 0.038
1.645 ± 0.565
6.296 ± 1.053

Table 2. Biodistribution of [18F]FTP in female Sprague-Dawley rats expressed as percent injected dose
per gram of tissue (%ID/g). Each set of data is the mean ± SD for n = 4 animals at each time point
Blood
Lung
Liver
Spleen
Kidney
Muscle
Fat
Heart
Brain
Bone
Marrow
Testes/Uterus
Prostate/Ovaries
Adrenals
Thyroid
Pancreas
Thymus
Stomach
Small intestine
Upper large intestine
Lower large intestine
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5 min
0.176 ± 0.041
5.948 ± 0.354
2.999 ± 0.414
2.693 ± 0.830
3.725 ± 0.321
0.176 ± 0.027
0.130 ± 0.018
1.169 ± 0.185
0.257 ± 0.023
0.564 ± 0.053
0.836 ± 0.214
0.152 ± 0.014
0.587 ± 0.247
3.767 ± 1.049
0.863 ± 0.158
1.893 ± 0.208
0.838 ± 0.081
0.372 ± 0.129
3.239 ± 0.500
0.703 ± 0.067
0.234 ± 0.007

30 min
0.176 ± 0.012
1.601 ± 0.057
2.257 ± 0.362
1.350 ± 0.248
2.513 ± 0.203
0.182 ± 0.022
0.189 ± 0.039
0.353 ± 0.025
0.171 ± 0.010
0.413 ± 0.020
0.689 ± 0.042
0.223 ± 0.010
0.734 ± 0.086
5.838 ± 0.698
0.305 ± 0.209
1.094 ± 0.062
0.695 ± 0.052
0.410 ± 0.085
4.986 ± 0.959
2.718 ± 0.972
0.202 ± 0.013

1 hour
0.146 ± 0.015
0.497 ± 0.075
1.359 ± 0.094
0.480 ± 0.102
1.733 ± 0.225
0.094 ± 0.011
0.105 ± 0.021
0.195 ± 0.023
0.134 ± 0.010
0.249 ± 0.017
0.412 ± 0.038
0.202 ± 0.011
0.736 ± 0.310
3.868 ± 1.002
0.238 ± 0.004
0.398 ± 0.067
0.511 ± 0.057
0.344 ± 0.079
3.283 ± 1.191
9.278 ± 1.151
0.255 ± 0.048

2 hours
0.068 ± 0.056
0.205 ± 0.178
0.611 ± 0.515
0.169 ± 0.147
0.679 ± 0.550
0.046 ± 0.038
0.043 ± 0.039
0.084 ± 0.071
0.064 ± 0.054
0.158 ± 0.132
0.143 ± 0.127
0.119 ± 0.101
0.340 ± 0.326
1.806 ± 1.551
0.097 ± 0.078
0.121 ± 0.106
0.225 ± 0.185
0.170 ± 0.163
0.848 ± 0.730
7.996 ± 6.584
0.356 ± 0.356

4 hours
0.070 ± 0.013
0.183 ± 0.023
0.707 ± 0.084
0.165 ± 0.014
0.770 ± 0.024
0.048 ± 0.007
0.026 ± 0.003
0.078 ± 0.010
0.083 ± 0.011
0.292 ± 0.025
0.084 ± 0.034
0.119 ± 0.017
0.088 ± 0.084
0.798 ± 0.345
0.127 ± 0.031
0.095 ± 0.016
0.158 ± 0.030
0.057 ± 0.017
0.392 ± 0.038
1.645 ± 0.565
6.296 ± 1.053
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Table 3. Organ residence times of [18F]FTP scaled
to human males and females based on male and
female rat biodistribution data
Residence Time Residence Time
Males-(min)
Females-(min)
Blood
5.2 ± 1.2
3.9 ± 0.5
Lung
8.2 ± 0.8
8.5 ± 1.9
Liver
18.8 ± 3.9
20.1 ± 3.5
Spleen
0.91 ± 0.24
1.15 ± 0.23
Kidney
3.4 ± 0.6
3.16 ± 0.49
Muscle
18.6 ± 4.3
11.0 ± 2.7
Fat
4.4 ± 1.3
3.19 ± 1.3
Heart
0.58 ± 0.11
0.56 ± 0.11
Brain
1.26 ± 0.25
1.05 ± 0.16
Bone
24.2 ± 4.5
18.57 ± 3.2
Marrow
2.73 ± 0.66
4.77 ± 1.1
Testes
0.05 ± 0.01
Prostate
0.064 ± 0.03
Adrenals
0.33 ± 0.11
0.233 ± 0.07
Thyroid
0.037 ± 0.012 0.039 ± 0.008
Pancreas
0.34 ± 0.05
0.35 ± 0.04
Thymus
0.061 ± 0.013
0.081 ± 0.01
Stomach
0.27 ± 0.106
0.54 ± 0.16
Small intestines
13.1 ± 5.6
14.0 ± 5.6
Upper large intestines
48.3 ± 25.2
68.8 ± 7.5
Lower large intestines
32.8 ± 3.1
38.6 ± 4.5
Uterus
0.21 ± 0.04
Ovaries
0.09 ± 0.02
Excreted
20
15
Remainder of the body
3.9
3.0
Organ

sum of observed residence times in specific
organs minus the excreted residence time.
The scaled human residence times from these
rodent experiments were entered in the program OLINDA/EXM 1.1 for F-18 in the adult
human male and female anthropomorphic
models [16].
Nonhuman primate tissue distribution
Two male and a female macaque fascicularis
underwent whole-body scanning for approximately 3 hrs using a Siemens MicroPET-F220.
The animals weighed 7.2 (male 1), 6.4 (male 2)
and 4.5 (female) kg, and received 167, 176 and
143 MBq of [18F]FTP respectively. The first animal (male 1) was scanned twice, and received
190 MBq of [18F]FTP for the second scan. The
animals were prepared for imaging as previously described [17, 18].
304

Data acquisition
Prior to radioligand injection, we collected
four 30 min transmission scans to cover
four body sections: A (whole brain), B (heart
and lungs), C (liver, gallbladder and kidneys),
and D (urinary bladder, small and large
intestines). Starting immediately after i.v.
injection of [18F]FTP, seven to eight sequential PET scans were performed for each of
the four sections (Figure 1). No loss of urine
or fecal matter was observed in the animals
during the scans. For one of the animals
(male 1), arterial blood samples were
obtained during a total scanning session of
approximately 4 hrs. Most of the blood samples were taken in the first 3 min to ensure
adequate description of the total radioactivity within the arterial blood compartment,
Afterwards, longer sampling times were
used over the 4 hrs study. The radioactivity
content in each blood sample was measured in a well counter that was cross-calibrated with the PET scanner.
PET image analysis
The reconstructed image resolution at the
center of the field of view for the PET studies
was < 2.0 mm full width half maximum
(FWHM) for all 3 dimensions. PET image
counts were calibrated to a dose calibrator
to facilitate comparison of PET measurements to MBq of F-18. For some organs
(whole brain, heart, lungs, urinary bladder),
regions of interest (ROIs) were drawn to entirely encompass the organ using ASIPro
VM™ MicroPET analysis software (Siemens
PreClinical Solutions, Knoxville, TN). For others
(liver, kidney, and gallbladder), we could not
delineate an appropriate ROI. Hence, we chose
several small representative ROIs that contained the highest observed radioactivity concentrations within the specific organ. The average radioactivity concentrations of these representative ROIs were multiplied by the entire
organ weight to give a liberal estimate of the
radioactivity within the total organ. This
approach will lead to slight overestimation of
the organ values, but the error in the estimate
tends toward increased subject safety.
The calculated activity in the whole organ was
plotted as a function of time to yield the organ
Am J Nucl Med Mol Imaging 2016;6(6):301-309
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time-activity curves. Organ
residence times were computed from the analytical integration of the multi-exponential
fitted onto the decay-corrected time-activity curves using
GraphPad Prism6 software.
The maximum theoretical residence time (T1/2/ln(2) = 2.64
hrs for F-18) minus the sum of
Figure 2. Blood time-activity curves for [18F]FTP expressed in percentage of
injected dose (%ID) per organ in male (A) and female (B) rats (n = 4 at each
measured residence times
time point).
was assigned to the remainder of the body as unspecific
activity. The urinary bladder time activity curve
Table 4. Estimated human absorbed radiation
was also fitted with an uptake function to prodose for [18F]FTP (mSv/MBq) from rodent biodisvide the MIRD bladder model parameters needtribution data
ed to calculate the bladder activity residence
Dose (mSv/MBq)
Organ
time. For this estimation, 2 hrs bladder voiding
Males
Females
intervals were used.
Adrenals
Brain
Breasts
Gallbladder wall
Lower large intestine wall
Small Intestines wall
Stomach Wall
Upper large intestine wall
Heart muscle
Kidneys
Liver
Lungs
Muscle
Ovaries
Pancreas
Red Marrow
Bones (osteogenic cells)
Skin
Spleen
Testes
Thymus
Thyroid
Urinary bladder wall
Uterus
Total Body

0.06
0.01
0.01
0.03
0.34
0.08
0.02
0.33
0.01
0.05
0.05
0.03
0.01
0.00
0.02
0.02
0.04
0.01
0.02
0.01
0.01
0.01
0.05
0.02
0.01

0.06
0.01
0.01
0.04
0.43
0.11
0.02
0.48
0.02
0.05
0.06
0.04
0.01
0.09
0.03
0.03
0.04
0.01
0.01
0.00
0.02
0.01
0.05
0.04
0.02

Table 5. Estimated effective dose and effective dose equivalent for [18F]FTP in human adult
males and females based on the rodent biodistribution data
Males Females
Effective Dose (mSv/MBq)
0.07
0.1
Effective Dose Equivalent (mSv/MBq) 0.064
0.1
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The blood time-activity curve for nonhuman primate data was integrated using the trapezoidal
rule to yield the blood residence time. The
blood activity in units of MBq/mL was converted to percent injected dose assuming a blood
volume of 8% of body weight and the injected
dose (175.5 MBq). Finally, 5% of the blood volume was assumed to be present in the left ventricle at all times.
The calculated residence times (T) were scaled
from animal to human based on the equation:
organ

body

M human M animal
(1)
organ m
body mc
M human M animal
Where T is the residence time and M is the
mass (organ or total body).
Thuman = Tanimal c

We used human male and female organ weights
in OLINDA/EXM [19] for the adult male and
adult female models. The percentage body
weight was applied for the kidney, liver, and
heart as reported previously for male and
female macaque fascicularis [20]. We used the
gallbladder and bladder percentages of total
body weight as determined ex vivo in the past,
and the organ weights for the brain and lungs
were based on their measured volume and an
assumed density of 1.0 g/cm3.
The scaled human residence times were
entered in the program OLINDA/EXM 1.1 for
F-18 following the adult human male and
female anthropomorphic models, with the
assumption that 10% of the blood residence
time is in the heart and bone activity is equal
Am J Nucl Med Mol Imaging 2016;6(6):301-309
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Figure 3. Different tissue
time-activity curves for [18F]
FTP. Decay-corrected activity is expressed as a percentage of injected dose
(%ID) per different organ of
a representative macaca
fascicularis.

residence times were observed in the small
and large intestines. Otherwise, the internal
organ with the largest accumulation was the
liver. The residence time in the blood was low at
approximately 0.17 min and was characterized
by a single exponential clearance with a biological half-life of 173 min for both male and female
groups (n = 4 at each time point) (Figure 2).

Figure 4. Blood time-activity curve based on arterial
blood sampling in a male macaca fascicularis following the intravenous injection of [18F]FTP.

part cortical and trabecular. The content within
the intestines was used as the source of
absorbed radiation to the intestines.
Results
Rodent biodistribution
The male and female rat biodistribution data
are presented in Tables 1 and 2, respectively.
The data is very similar for the two species.
Both show predominant accumulation of radioactivity in the small intestines which peaks at
30 minutes, followed by accumulation in the
upper large intestine that is maximum at about
1 hr. There was relatively modest localization of
activity in liver and kidney.
Residence times and dosimetry from rodent
biodistribution data
Organ residence times scaled to human organ
weights are presented in Table 3. In The largest
306

For the male group, the fit on urine data provided A0 = 22%ID and A1 = 0.90 hr-1 with a bladder residence time of 4.6 min and an excreted
residence time of 20.0 min. The fit on the feces
data provided A0 = 0.07%ID and A1 = 0.5 hr-1
with an excreted residence time of 0.063 min.
Combined data for urine and feces resulted in
an excreted residence time of 20 min. For the
female group, the fit of the urine data provided
A0 =15%ID and A1 = 1.12 hr-1 with a bladder
residence time of 2.85 min and an excreted
residence time of 14.9 min. The fit of the feces
data provided A0 = 0.04%ID and A1 = 0.75 hr-1
with an excreted residence time of 0.042 min.
Combined data for urine and feces resulted in
an overall excreted residence time of 15 min.
Estimates of human organ absorbed radiation
doses for the adult human male and female are
presented in Tables 4 and 5, respectively. The
uncertainty of the dose estimates is proportional to the uncertainties in the respective
organ residence times.
Nonhuman primate biodistribution
The representative sagittal image of [18F]FTP
indicates the macaque fascicularis has relative
high gallbladder uptake within 10 min data collection at 190 min post injection shown in
Figure S1A and representative transverse
Am J Nucl Med Mol Imaging 2016;6(6):301-309
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Table 6. Organ residence times (hr) for [18F]FTP in based on
PET image data from macaque fascicularis
Organ
Liver
Heart
Rain
Lungs
Gallbladder
Kidneys
Urinary bladder
Blood assigned to the left ventricle cavity
Remainder of the body

Rat ex vivo biodistribution data
showed that [18F]FTP was retained
predominantly in the intestines,
suggesting relatively rapid clearance of the radioactivity from the
liver into the small intestines and
subsequent transfer to the large
intestines. The organ having the
largest absorbed radiation dose
was the wall of the large intestines
for both male and females, making
the intestines the dose limiting
organ (0.32-0.49 mGy/MBq). As
an estimate of human dosimetry,
the Effective Dose (ED) was 0.07
mSv/MBq in male and 0.1 mSv/MBq in female.
Although the rodent data indicates a maximum
injected dose of 480 MBq to correspond to an
effective dose (ED) below 50 mSv, the radiation
dose to the intestes is the dose limiting factor.
Indeed, the rat model projects an injected dose
of 111 MBq will result in a radiation dose of
approximately 50 mGy to the intestinal wall,
with less than 30 mGy delivered to the gonads,
red marrow or whole body.

Residence Time (hr)
#1
#2
#3
(male) (male) (female)
1.85 1.27
1.83
0.02 0.09
0.02
0.04 0.05
0.07
0.05 0.07
0.01
0.15 0.02
0.38
0.13
0.19
0.11
0.13 0.06
0.21
0.002 0.002 0.002
0.26 0.87
0.01

Table 7. Effective dose and effective dose
equivalent for [18F]FTP in human adult males and
females estimated from in vivo distribution data
in macaque fascicularis
Males Females
Effective Dose (mSv/MBq)
0.26
0.37
Effective Dose Equivalent (mSv/MBq) 0.24
0.37

image of [18F]FTP indicates animal has high
lung uptake with 2 min data collection beginning 6 min post injection Figure S1B.
Figure 3 shows the time activity curves compiled from sequential imaging of a male macaca fascicularis. The time activity data were fitted with a function composed of single or combined exponentials. Least square minimization
was performed to find the best fitting parameters.
Residence times and dosimetry estimation
The time-activity data for blood was collected
for the second male macaca fascicularis only,
and is shown in Figure 4. We calculated a heart
chamber residence time of 0.091 min based on
the blood residence time of 1.82 min, a value
that was employed for all the animals. The calculated residence times are reported in Table
6.
Human adult male and female absorbed radiation dosimetry was estimated from data derived
from residence times for the animals and the
OLINDA/EXM model. These data are presented
in Table 7.
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Discussion

By contrast, data from the imaging studies of
nonhuman primate demonstrated high retention of the radiotracer in the liver and gallbladder, indicating predominant hepatobiliary clearance. The image data from the macaque studies demonstrate a much longer residence time
in the liver, and the absence of activity in the
intestines. These findings reflect the much
slower transfer of [18F]FTP and/or its radioactive metabolites through the hepatobiliary track
in primates compared to rodents. As a result of
this difference in tracer disposition, the critical
organ based on the macaque data was the
gallbladder wall (estimated human dose 2.78
mGy/MBq) and a lower Effective Dose (0.02
mSv/MBq) compared to estimates based on
rodent data. An injected dose of 181 MBq of
[18F]FTP will yield a an estimated human
absorbed radiation dose of approximately 50
mGy to the gallbladder, and less than 30 mGy
to the gonads, red marrow or whole body.
Conclusions
The human absorbed radiation dosimetry of
new radiopharmaceutical can be estimated in
preclinical studies of radiotracer disposition in
Am J Nucl Med Mol Imaging 2016;6(6):301-309
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rodent and nonhuman primate. In these measurements, it is important to be aware of species differences when estimating human
dosimetry. As this study of the D3 radioligand
[18F]FTP shows, dramatic differences can arise
in human dose estimates based on rodent and
nonhuman primate models. The discrepancy
between the critical organs estimated using
rodent and nonhuman primate data most likely
reflects the lack of a gallbladder in rodents.
This crucial observation is a caveat against
estimation of human dosimetry from rodent
data for radiopharmaceuticals with hepatobiliary clearance.
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Figure S1. A. Representative Sagittal PET Image of [18F]FTP in the abdomen of monkey. Sagittal view through abdomen with left of image toward the abdominal wall and right of the image to the back. This is a PET image with 10 min
data collection beginning with 190 min post [18F]FTP administration. The arrow indicates uptake of [18F]FTP in the
gallbladder. The lower warm spot is in the bowel. Warmer colors indicate higher uptake. The image is scaled to the
slice maximum. The bony spine shows as white on the right of the attenuation image. B. Representative transverse
PET Image of [18F]FTP in the abdomen of monkey. Transverse view through chest with top of the image toward the
abdominal wall and bottom of the image to the back. This is a PET image with 2 min data collection beginning 6
min after [18F]FTP administration. The arrow indicates the left lung. The animal is lying supine in the scanner which
increases the blood flow toward the back (due to gravity). The lungs have high uptake of [18F]FTP in this early scan.
Warmer colors indicate higher uptake. The image is scaled to the slice maximum.
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